TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29330573
Drug: Low TT
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low TT (430 mg TT/day, 70% purity)
Study: 29330573
Drug: High TT
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High TT (860 mg TT/day, 70% purity)
Study: 26739235
Drug: Mini-tablets (MTs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-tablets (MTs)
Study: 26739235
Drug: Orally disintegrating
Normalized name: Clozapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally disintegrating mini-tablet (ODMT)
Study: 21371548
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet (CT)
Study: 26739235
Drug: Conventional orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional orally disintegrating tablet (ODT)
Study: 22479925
Drug: Glucantime (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime (5 days of intralesional administration)
Study: 12119306
Drug: Pharmacotherapy for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy for bulimia nervosa
Study: 12119306
Drug: Combined pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacotherapy and short-term psychotherapy
Study: 9717330
Drug: Amoxicillin-clavulanate for
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate for 24 hours
Study: 8023058
Drug: Beta-carotene levels
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene levels in patients (0.36 microgram/g biopsy)
Study: 8023058
Drug: Alpha-tocopherol levels
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol levels in patients (237.5 micrograms/g biopsy)
Study: 8023058
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplement consumption
Study: 2455151
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR (to 240 mg b.i.d.)
Study: 2455151
Drug: Metoprolol (to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (to 100 mg b.i.d.)
Study: 27532880
Drug: MusicGlove therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MusicGlove therapy
Study: 23325911
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) intervention delivered by a nurse therapist, up to 12 sessions.
Study: 23325911
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) intervention.
Study: 21523723
Drug: Dasatinib (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (administered orally or via percutaneous feeding gastrostomy)
Study: 21523723
Drug: Dasatinib (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (administered via percutaneous feeding gastrostomy)
Study: 19907042
Drug: Revascularization plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization plus medical therapy
Study: 16951015
Drug: Topical retinoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoid
Study: 16951015
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (topical retinoid + antimicrobial agent)
Study: 16951015
Drug: Topical retinoids
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoids (maintenance therapy)
Study: 15234416
Drug: Tedisamil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil 0.4 mg/kg
Study: 15234416
Drug: Tedisamil 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil 0.6 mg/kg
Study: 9377539
Drug: Dextroamphetamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (10 mg doses)
Study: 30977770
Drug: Baclofen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30 mg/day or 75 mg/day)
Study: 26899588
Drug: Early medication
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early medication change (EMC) strategy: venlafaxine XR for study days 15‐56; lithium augmentation for days 29‐56 if sustained non‐improvement on day 28.
Study: 26899588
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU): continuation of escitalopram; non-responders on day 28 switched to venlafaxine XR for four weeks (days 29‐56).
Study: 24548534
Drug: Community Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Health Worker (CHW) intervention consisting of five monthly group educational sessions, two one-on-one visits, and follow-up phone calls over six months.
Study: 20197015
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of normal-dose telmisartan (40 mg) and low-dose hydrochlorothiazide (12.5 mg) once daily for 12 weeks
Study: 17284896
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion technique for measuring glomerular filtration rate and renal plasma flow
Study: 16899775
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of atorvastatin per day
Study: 25720557
Drug: Concurrent neck
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent neck dissection during TORS (control group)
Study: 23091109
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m², thalidomide 100 mg, and dexamethasone 40 mg (VTD)
Study: 23091109
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m², thalidomide 100 mg, and dexamethasone 40 mg with cyclophosphamide 400 mg/m² (VTDC)
Study: 21723605
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of donepezil (10 mg)
Study: 21723605
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of donepezil (10 mg)
Study: 12653691
Drug: Caffeine-replete (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-replete (200 mg caffeine capsules twice daily)
Study: 11885175
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in augmented maxillary sinuses using various grafting materials (autogenous bone, DFDBA, HA, combination grafts)
Study: 11885175
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed in the posterior maxilla without sinus grafting
Study: 11885175
Drug: Overall implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall implants placed
Study: 8807564
Drug: Mineral tablets
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral tablets containing calcium, potassium and sodium phosphates (Redusan Combi) during first 4 weeks
Study: 8807564
Drug: Placebo first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo first and mineral tablets in the final period (group 2)
Study: 1570233
Drug: Experimental buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental buccal formulation of piroxicam (20 mg daily)
Study: 1570233
Drug: Oral capsules
Normalized name: Plenity Oral Capsules
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsules of piroxicam (20 mg daily)
Study: 6367129
Drug: Saline (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (same volume as cefuroxime, administered by the same route)
Study: 6367129
Drug: Antibiotic treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic treated group (cefuroxime)
Study: 24517291
Drug: Low-dose NCCT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NCCT (5, 7.5, 15, 30, 50, 70, and 140 mAs)
Study: 24517291
Drug: Conventional-dose NCCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose NCCT (not explicitly defined in terms of mAs)
Study: 9513626
Drug: Take-home medication
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home medication
Study: 12450962
Drug: Dose increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose increase
Study: 9513626
Drug: Additional service
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional service items (e.g., rent, food or gas payments; employment assistance; medical care)
Study: 8061173
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (120 mg q.i.d.) and amoxycillin (500 mg q.i.d.)
Study: 3288467
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release nifedipine 20mg twice daily
Study: 31269364
Drug: Rituximab (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (two infusions, 1000 mg each, administered 14 days apart; repeated at 6 months in case of partial response)
Study: 31269364
Drug: Cyclosporine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (starting at a dose of 3.5 mg per kilogram of body weight per day for 12 months)
Study: 24555233
Drug: Bolus intravenous
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous administration of cytoflavin
Study: 24555233
Drug: Dropwise intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dropwise intravenous injection of cytoflavin
Study: 21240870
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate 30 mg daily, titrated to a maximum dosage of 120 mg daily for 24 weeks.
Study: 18048424
Drug: Creatine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (2 g/day)
Study: 16982453
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIG) at a daily dose of 400 mg/kg for 2-3 times
Study: 11022778
Drug: SDD 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDD 10 mg qd
Study: 11022778
Drug: SDD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDD 20 mg qd
Study: 11022778
Drug: SDD 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDD 20 mg bid
Study: 7525886
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2 during every other cycle) with 5-FU (800 mg/m2/d) and HU (escalating doses) and concomitant radiotherapy (1.8 to 2.0 Gy on days 1 to 5) plus G-CSF (5 micrograms/kg/d on days 6 to 13)
Study: 7525886
Drug: 5-FU (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (800 mg/m2/d) and HU (escalating doses) and concomitant radiotherapy (1.8 to 2.0 Gy on days 1 to 5) without G-CSF
Study: 19302707
Drug: IFN beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta‐1a 44 mcg biw
Study: 19302707
Drug: IFN beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta‐1a 44 mcg tiw
Study: 19302707
Drug: IFN beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN beta‐1a 66 mcg tiw
Study: 7695422
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (16 mmol continuously from anesthetic induction to aortic cross‐clamping, followed by 32 mmol starting after release of aortic cross‐clamp until 24 hours later)
Study: 7695422
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (Group A)
Study: 1015538
Drug: Postoperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative systemic BCG adjuvant immunotherapy
Study: 27808588
Drug: Myo-inositol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (4 g/day)
Study: 12091045
Drug: 3.500 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.500 IU anti‐Xa of tinzaparin (Innohep) subcutaneously once daily
Study: 2403851
Drug: 0 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 ml.kg‐1 apple juice
Study: 2403851
Drug: 6 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 ml.kg‐1 apple juice
Study: 2403851
Drug: 10 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml.kg‐1 apple juice
Study: 341903
Drug: Halopredone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halopredone acetate (0.05% in cream)
Study: 341903
Drug: Fluocinonide (0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinonide (0.05% in cream)
Study: 19356750
Drug: Needle-free CO(2)
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-free CO(2) injection system (Biojector 2000)
Study: 19356750
Drug: Traditional sharp
Normalized name: shark preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional sharp needles for gonadotropin injections
Study: 12471719
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group (vegetable drink with 0.5 g of sardine peptides and 0.4 mg of VY)
Study: 12471719
Drug: Excessive ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excessive ingestion test (585 g of test drink for 14 days)
Study: 12471719
Drug: Excessive ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excessive ingestion test (585 g of control drink for 14 days)
Study: 8573948
Drug: 2-hour amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-hour amphotericin B infusions
Study: 8573948
Drug: 4-hour amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-hour amphotericin B infusions
Study: 8573948
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment regimens
Study: 29150536
Drug: Treatment regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimens
Study: 2617169
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.m. + Amoxicillin 750 mg b.i.d (Group 1)
Study: 2617169
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg b.i.d (Group 3)
Study: 2617169
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.m. (Group 2)
Study: 321487
Drug: Indoprofen (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (three dose levels)
Study: 321487
Drug: ASA (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA (three dose levels)
Study: 27105332
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omega‐3 and PEP
Study: 29625834
Drug: Guided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-based cognitive behavioral treatment (ICBT) for 12 weeks
Study: 29625834
Drug: Unguided Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided Internet-based cognitive behavioral treatment (ICBT) for 12 weeks
Study: 24609919
Drug: 12 month
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 month intervention group (three face to face visits with a lifestyle counsellor plus monthly 15 minute telephone calls)
Study: 19369056
Drug: EGG group
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGG group (640 mg additional cholesterol)
Study: 11880821
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g x kg(‐1) x d(‐1) for 7 days)
Study: 10511768
Drug: Captopril (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (0.7 mg/kg)
Study: 10511768
Drug: Captopril (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (0.7 mg/kg) and Furosemide (1 mg/kg)
Study: 26932302
Drug: Empagliflozin 12.5
Normalized name: empagliflozin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 12.5 mg/metformin 1,000 mg FDC
Study: 26932302
Drug: Individual tablets
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual tablets of empagliflozin and metformin
Study: 18434221
Drug: Active physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active physical treatment (APT) - 10 weeks of aerobic training and muscle strengthening of back extensors
Study: 18434221
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (CT) - APT combined with GAP
Study: 16306196
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with indomethacin (0.1 mg/kg/24 h for three doses) and L‐NMMA (infusion for 72 hours)
Study: 16306196
Drug: Indomethacin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.1 mg/kg/24 h for three doses)
Study: 10099034
Drug: Nicardipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (60 or 90 mg/d)
Study: 6232263
Drug: Nomifensine maleate
Normalized name: nomifensine maleate
DrugBank: Nomifensine (DB04821)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nomifensine maleate (100-200 mg/day)
Study: 31421635
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) treatment (250 mg for 2 days, 500 mg for 2 days, 750 mg for 3 days, and 1000 mg for 5 weeks)
Study: 29247343
Drug: Caffeine-maltodextrin mouth
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-maltodextrin mouth rinse (MR: 0.3 g/25 ml CAF: 1.6g/25 ml MALT)
Study: 29247343
Drug: Placebo (PLAC:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLAC: 25 ml artificial saliva)
Study: 27965251
Drug: AKUD trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKUD trial (app‐administered self‐care acupressure)
Study: 23886416
Drug: 4.3 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.3 Gy × 10 fractions (target dose 43 Gy)
Study: 23886416
Drug: 2.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 Gy × 20 fractions (target dose 50 Gy)
Study: 17694310
Drug: Gefitinib 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 1000 mg/day with temozolomide for patients on EIAEDs
Study: 17694310
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg/day with temozolomide for patients not on EIAEDs
Study: 17694310
Drug: Gefitinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib and temozolomide combination
Study: 17019957
Drug: Low‐intensive laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐intensive laser radiation (LILR) monotherapy
Study: 17019957
Drug: Low‐intensive laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐intensive laser radiation (LILR) plus conventional drug therapy (CDT)
Study: 17019957
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy (CDT) only
Study: 10780761
Drug: zafirlukast 80
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zafirlukast 80 mg
Study: 10780761
Drug: zafirlukast 20
Normalized name: zafirlukast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: zafirlukast 20 mg
Study: 25291130
Drug: Active formulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active formulation containing 250 mg of tara gum and 1 billion viable cells of S. thermophilus ST10
Study: 22837118
Drug: Meperedine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperedine (0.4 mg/Kg/IV)
Study: 22837118
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg/IV)
Study: 18038601
Drug: N-acetylcysteine in
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine in complex therapy
Study: 16129716
Drug: High-calcium diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium diet (1400 mg of calcium)
Study: 16129716
Drug: Moderate-calcium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-calcium diet (800 mg of calcium)
Study: 16129716
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (standard diet with 800 mg of calcium)
Study: 11872102
Drug: 2 mL/hour
Normalized name: bupivacaine HCl/PF 0.5 % 2 mL/hour 100 mL INJECTION ELASTOMERIC PUMP, FIXED RATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL/hour
Study: 11872102
Drug: 20 mL/hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL/hour
Study: 11872102
Drug: 50 mL/hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL/hour
Study: 11872102
Drug: 100 mL/hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL/hour
Study: 11872102
Drug: All administration
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All administration sets
Study: 3416310
Drug: 10-ethyl-10-deazaaminopterin (10-EDAM)
Normalized name: ethyl 10-undecenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-ethyl-10-deazaaminopterin (10-EDAM) i.v. at dosage levels ranging from 5 to 120 mg/m2
Study: 3416310
Drug: 10-EDAM i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-EDAM i.v. weekly x 3 schedule (35 patients) or weekly schedule (27 patients)
Study: 3416310
Drug: 10-EDAM i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-EDAM i.v. weekly at 80 mg/m2 or 100 mg/m2 weekly for 3 weeks
Study: 3416310
Drug: Pharmacokinetic studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacokinetic studies at 5, 30, and 100 mg/m2 dosage levels
Study: 19816648
Drug: Monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly ibandronate 150 mg for 3 months
Study: 19816648
Drug: Weekly risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly risedronate 35 mg for 12 weeks
Study: 16831952
Drug: Monthly ibandronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly ibandronate